Plain-English translation of NCT07035691 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research trial is testing two new blood biomarkers — hPG80 and transposable elements — to see if they can more accurately detect bowel cancer in patients who have been referred for urgent evaluation. Right now, doctors use a stool test followed by invasive procedures like colonoscopy, but most patients referred don't actually have cancer. These blood tests could help identify who really needs further investigation and who doesn't.
Currently, only about 1 in 10 patients referred through urgent bowel cancer pathways actually have cancer, which means many people undergo unnecessary invasive procedures, experience anxiety, and add pressure to an already stretched healthcare system. This trial exists to find a better, less invasive blood test that can accurately separate patients who truly need further testing from those who don't.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will have one additional blood sample taken alongside your usual bowel cancer investigations — no extra visits needed. The researchers will analyze your blood using new genetic sequencing techniques to see if these markers can predict whether you have cancer or polyps. You'll continue with your normal diagnostic pathway (like colonoscopy if recommended) and receive your results as usual.
AI-generated summary from trial data · Aug 17, 2026 · Not medical advice
United Kingdom